Latest news

Nucleai Secured $6.5m Series-A Initial Closing Led by Debiopharm to Advance Ai-Powered Precision Oncology Platform

Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders

Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer

Acquisition of Debiopharm’s Investment Portfolio Company Kaiku Health Broadens Patient Access to Digital Oncology Intervention

Le Challenge pour la Qualité de vie du patient 2020 est maintenu et le délai de remise des projets prolongé…

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

FDA grants Breakthrough Therapy Designation for Debiopharm’s novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer

Challenge pour la Qualité de vie du patient 2020 : l’appel à projets est ouvert